What is Cour?
Cour Pharmaceuticals is at the forefront of developing targeted therapies designed to reprogram the immune system and restore health in individuals afflicted with autoimmune diseases. Their proprietary platform technology utilizes an antigen-specific methodology to address the root causes of these conditions while preserving essential immune functions. The company's primary focus is on pioneering next-generation disease-modifying treatments to establish new standards of care for a spectrum of immune-mediated disorders. Cour Pharmaceuticals is dedicated to ensuring that patients, irrespective of the rarity or complexity of their condition, have access to safer and more effective therapeutic options.
How much funding has Cour raised?
Cour has raised a total of $185M across 2 funding rounds:
Unspecified
$30M
Series A
$105M
Unspecified (2022): $30M with participation from Alpha Wave Ventures
Series A (2024): $105M led by Alpha Wave Global and Lumira Capital
Key Investors in Cour
Alpha Wave Global
Alpha Wave Global is an investment firm that has participated in Cour Pharmaceuticals' recent funding round. Further details on their specific investment focus are not provided.
Lumira Capital
Lumira Capital is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech, biotherapeutics, and medical devices. The firm partners with mission-driven entrepreneurs to develop and commercialize impactful products aimed at improving patient outcomes.
Alpha Wave Ventures
Alpha Wave Ventures is an investor in Cour Pharmaceuticals, contributing to the company's funding rounds. Specific details regarding their investment thesis are not available.
What's next for Cour?
The substantial enterprise-level backing and recent strategic investment position Cour Pharmaceuticals for accelerated growth and the advancement of its therapeutic pipeline. This infusion of capital is expected to fuel further research and development, clinical trials, and potential commercialization efforts for their innovative autoimmune disease treatments. The company's commitment to reprogramming the immune system suggests a focus on expanding its platform's applicability to a wider range of immune-mediated conditions, potentially transforming the treatment landscape for millions of patients worldwide. Future developments will likely center on progressing their lead candidates through regulatory pathways and establishing strategic partnerships to maximize market reach.
See full Cour company page
